Skip to main content
logo
Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
16.28
+0.49 (3.10%)
At close: Sep 2, 2026, 4:00 PM EDT
16.32
+0.04 (0.25%)
Pre-market: Sep 3, 2026, 8:51 AM EDT

Generate Biomedicines Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-237.74-203.15-173.77
Depreciation & Amortization
12.9413.1815.35
Loss (Gain) From Sale of Assets
-0.06-0.06-0.01
Loss (Gain) From Sale of Investments
-1.6-2.78-5.45
Stock-Based Compensation
24.9820.5819.47
Other Operating Activities
-4.61-13.76-1.45
Change in Accounts Receivable
0.340.31-0.21
Change in Accounts Payable
-0.18-2.133.5
Change in Unearned Revenue
-26.48-31.8934.54
Change in Other Net Operating Assets
-4.619.1-9.71
Operating Cash Flow
-237.02-200.62-117.75
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-7.32-3.51-3.45
Sale of Property, Plant & Equipment
--0.01
Investment in Securities
-161120.28-54.29
Investing Cash Flow
-168.32116.77-57.73

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Long-Term Debt Repaid
--8.16-11.12
Net Debt Issued (Repaid)
-5.21-8.16-11.12
Issuance of Common Stock
373.381.11.13
Other Financing Activities
17.8713.125
Financing Cash Flow
386.0728.0691.33

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
-19.27-55.79-84.15

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-244.35-204.13-121.2
Free Cash Flow Growth
---
Free Cash Flow Margin
-922.65%-640.06%-592.39%
Free Cash Flow Per Share
-2.98-4.08-2.49
Levered Free Cash Flow
--119.1-
Unlevered Free Cash Flow
--118.39-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash Income Tax Paid
0.160.160.21
Change in Working Capital
-30.92-14.6228.12
SEC Filings: 10-K · 10-Q